Search for: "K-V Pharmaceutical Company" Results 41 - 60 of 221
Sort by Relevance | Sort by Date
RSS Subscribe: 20 results | 100 results
8 Mar 2018, 11:35 am by Ad Law Defense
”  Organic Consumers Association et al v. [read post]
28 Apr 2017, 6:01 am by John Duffy
One of the very first steps in the statutory “exchange of information” process is that the applicant for a biosimilar license – here Sandoz – “shall provide to the [research pharmaceutical company] a copy of the application submitted [to the agency] under subsection (k). [read post]
24 Apr 2017, 11:12 am by John Duffy
Subsection (l) provides a process by which the applicant for a biosimilar license (i.e., the generic pharmaceutical company) can exchange information about patents with the company that first obtained FDA approval to market the original biologic drug (i.e., the research pharmaceutical company). [read post]
4 Apr 2017, 2:51 am by Thomas Musmann
Even though the award dismisses all claims, which the US pharmaceutical company Eli Lilly had asserted against Canada, these arbitral proceedings set the standards for litigating patents under international investment law in the future. [read post]
12 Mar 2017, 9:28 am
 On the 26 April 2017, the US Supreme Court will hear arguments on this issue in Sandoz v Amgen. [read post]
7 Mar 2017, 3:16 am by Dennis Crouch
(Daily.2016.Professors) Tristan Gray–Le Coz and Charles Duan, Apply It to the USPTO: Review of the Implementation of Alice v. [read post]
2 Jun 2016, 5:23 am by Mary Jane Wilmoth
Banc de Binary Ltd, Oren Shabat Laurent (f/k/a Oren Shabat), Et Binary Options Ltd., Bo Systes Ltd., Seychelles and BDB Services Ltd. [read post]